HeartSciences has announced that it has been highlighted as a “Start-Up to Watch” in the June 8, 2018 issue of the MedTech Strategist. The article titled “Heartsciences: artificial intelligence improves frontline risk stratification for heart diseases” discusses HeartSciences’ role in addressing the current challenges and significant unmet need to identify heart disease at an early stage and reduce the high prevalence of expensive diagnostic testing with low yields.
The article highlights the enormous opportunity for HeartSciences’ breakthrough MyoVista Wavelet ECG (wavECG) technology to benefit patients and to reduce health system costs and references a recently published study titled “Prediction of Abnormal Myocardial Relaxation From Signal Processed Surface ECG” in the Journal of American College of Cardiology.
“It is an honour to be recognised by MedTech Strategist as a Start-Up to Watch,” said Mark Hilz, CEO. HeartSciences is working to bridge today’s “diagnostic gap” in cardiac care by providing low-cost effective solutions that help to identify patients prior to experiencing an adverse cardiac event, such as a heart attack.
Mary Stuart wrote in the MedTech Strategist,“The current screening paradigm for heart disease is missing people at early stages, when diseases are most treatable. HeartSciences has taken a ubiquitous screening tool, the 12-lead ECG, and has, through the application of signal processing and artificial intelligence, turned it into a powerful tool that can detect diastolic dysfunction, an early indicator of most cardiac diseases.”
